Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
26CA Stock Chart & Stats
€7.32
-€0.11(-4.34%)
At close: 4:00 PM EST
€7.32
-€0.11(-4.34%)
Day’s Range― - ―
52-Week Range€1.63 - €7.18
Previous CloseN/A
Volume0.00
Average Volume (3M)9.19K
Market Cap
€7.15B
Enterprise Value€9.05B
Total Cash (Recent Filing)€257.81M
Total Debt (Recent Filing)€542.25M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 03, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding984,965,150
10 Day Avg. Volume5,563
30 Day Avg. Volume9,189
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-3.65
Price to Sales (P/S)121.07
P/FCF Ratio-4.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.42Price Target Upside1.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Durability And Bladder PreservationLong‑term follow‑up data show high bladder cancer‑specific survival and strong avoidance of cystectomy with ANKTIVA plus BCG, supporting durable clinical benefit that can drive sustained physician use.
Commercial MomentumRapidly growing sales and rising unit volumes indicate accelerating physician adoption and improving market access, suggesting ANKTIVA is transitioning from a one‑time launch to an established commercial franchise.
Regulatory ValidationEuropean regulators issued a positive opinion recommending conditional marketing authorization for ANKTIVA plus BCG in BCG‑unresponsive non‑muscle invasive bladder cancer, expanding the therapy's commercial footprint and strengthening global regulatory credibility.
Bears Say
Mechanism And Endpoint UncertaintyQuestions remain about whether immune restoration will be broadly accepted by regulators and clinicians and whether lymphocyte count can serve as a reliable endpoint, which could constrain label expansion across tumor types.
Post‑marketing And Confirmatory Data RiskConditional authorization requires post‑marketing commitments with unclear timing and scope for confirmatory data submissions, creating regulatory and commercial risk if required studies are delayed or do not meet expectations.
Reimbursement And Launch Execution RiskUncertainty about national reimbursement decisions and the pace and structure of the European launch could limit market penetration and temper early commercial expectations for ANKTIVA.
ImmunityBio News
26CA FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.63 and its highest was €7.18 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is €7.15B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Mar 03, 2026 which is in 8 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Nov 04, 2025. The company reported -€0.059 earnings per share for the quarter, beating the consensus estimate of -€0.09 by €0.031.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.08.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 984,965,150 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -€0.059 in its last earnings report, beating expectations of -€0.09. Following the earnings report the stock price went down -8.163%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in DE:26CA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.42 (1.40% Upside)
€7.42 (1.40% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 83%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.36%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
26CA Stock 12 Month Forecast
Average Price Target
€7.42
▲(1.40% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---